K. pneumoniae liver abscess following deferoxamine subcutaneous self‐injection
Ludovico Furlan,Ludovico Furlan,Giovanna Graziadei,Giulia Colombo,Giulia Colombo,Laura Forzenigo,Monica Solbiati,Monica Solbiati +7 more
Reads0
Chats0
TLDR
Dipartimento di Medicina Interna e Specializzazioni Mediche, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milano, Italy; Dipartimenti di Scienze Cliniche e di Comunit a, Universit a degli Studi di MilanoAbstract:
Dipartimento di Medicina Interna e Specializzazioni Mediche, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milano, Italy; Dipartimento di Scienze Cliniche e di Comunit a, Universit a degli Studi di Milano, Milano, Italy; Centro Anemie Congenite, Dipartimento di Medicina Interna e Specializzazioni Mediche, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milano, Italy; Dipartimento di Radiologia, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milano, Italy Correspondence Ludovico Furlan, Dipartimento di Medicina Interna e Specializzazioni Mediche, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Via Francesco Sforza 35, 20122 Milano, Italy. Email: ludovico.furlan@unimi.itread more
References
More filters
Journal ArticleDOI
Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies.
Johan R. Boelaert,M. de Locht,J. Van Cutsem,V Kerrels,B. Cantinieaux,A. K. Verdonck,H. W. van Landuyt,Yves-Jacques Schneider +7 more
TL;DR: Pharmacokinetic changes in uremia lead to a prolonged accumulation of Fe.DFO after DFO administration, which helps explain the increased sensitivity of dialysis patients to DFO-related mucormycosis.
Journal ArticleDOI
Desferrioxamine and systemic yersiniosis
Journal ArticleDOI
Infection Due to Yersinia enterocolitica in a Series of Patients with α-Thalassemia: Incidence and Predisposing Factors
Thomas V. Adamkiewicz,Mati Berkovitch,Chandar Krishnan,Christina Polsinelli,Dee Kermack,Nancy F. Olivieri +5 more
TL;DR: Iron-loaded patients with beta-thalassemia are at greatly increased risk for severe yersiniosis, even when their body iron burden is only moderately elevated and they are not receiving iron-chelating therapy with deferoxamine.
Journal ArticleDOI
Effects of Chelators (Deferoxamine, Deferiprone and Deferasirox) on the Growth of Klebsiella Pneumoniae and Aeromonas Hydrophila Isolated from Transfusion-Dependent Thalassemia Patients
TL;DR: It is suggested that factors other than DFO may account for the increased prevalence of Klebsiella and Aeromonas infection in Asian thalassemic patients.
Journal ArticleDOI
Yersinia infections in patients with homozygous beta-thalassemia associated with iron overload and its treatment.
TL;DR: Recognition of this association and unusual manifestations in these patients such as an appendicitis-like syndrome may direct clinicians to earlier antiyersinial therapy and temporary cessation of chelation.